- Home
- VRTX vs GILD Comparison
VRTX vs GILD Comparison
Compare VRTX & GILD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRTX
- GILD
- Stock Information
- Founded
- VRTX 1989
- GILD 1987
- Country
- VRTX United States
- GILD United States
- Employees
- VRTX N/A
- GILD N/A
- Industry
- VRTX EDP Services
- GILD Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- VRTX Technology
- GILD Health Care
- Exchange
- VRTX Nasdaq
- GILD Nasdaq
- Market Cap
- VRTX 119.6B
- GILD 113.0B
- IPO Year
- VRTX 1991
- GILD 1992
- Fundamental
- Price
- VRTX $396.64
- GILD $91.09
- Analyst Decision
- VRTX Buy
- GILD Buy
- Analyst Count
- VRTX 30
- GILD 26
- Target Price
- VRTX $519.12
- GILD $96.71
- AVG Volume (30 Days)
- VRTX 1.5M
- GILD 6.4M
- Earning Date
- VRTX 02-03-2025
- GILD 02-11-2025
- Dividend Yield
- VRTX N/A
- GILD 3.38%
- EPS Growth
- VRTX N/A
- GILD N/A
- EPS
- VRTX N/A
- GILD 0.10
- Revenue
- VRTX $10,625,800,000.00
- GILD $28,299,000,000.00
- Revenue This Year
- VRTX $12.54
- GILD $6.54
- Revenue Next Year
- VRTX $8.52
- GILD N/A
- P/E Ratio
- VRTX N/A
- GILD $937.76
- Revenue Growth
- VRTX 10.06
- GILD 3.31
- 52 Week Low
- VRTX $378.00
- GILD $62.07
- 52 Week High
- VRTX $519.88
- GILD $98.90
- Technical
- Relative Strength Index (RSI)
- VRTX 23.70
- GILD 49.02
- Support Level
- VRTX $459.79
- GILD $89.15
- Resistance Level
- VRTX $474.19
- GILD $93.59
- Average True Range (ATR)
- VRTX 12.03
- GILD 2.14
- MACD
- VRTX -4.30
- GILD -0.25
- Stochastic Oscillator
- VRTX 18.93
- GILD 35.27
About VRTX Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).